Testosterone therapy in the aging male

References

• Nieschlag E, Lammers U, Freischem C W, et al. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 1982; 55: 676–681
   PubMed Web of Science ®Google Scholar
• Gray A, Berlin J A, McKinlay J B, et al. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44: 671–684
   PubMed Web of Science ®Google Scholar
• Mohr B A, Guay A T, O'Donnell A B, et al. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Aging Study. Clin Endocrinol 2005; 62: 64–73
   PubMed Web of Science ®Google Scholar
• Morley J E, Kaiser F E, Perry H M, III, et al. Longitudinal changes in testosterone, luteinizing hormone and follicle-stimulating hormone in healthy older men. Metabolism 1997; 46: 410–413
   PubMed Web of Science ®Google Scholar
• Harman S M, Metter E J, Tobin J D, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001; 86: 724–731
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocrinol Rev 2005; 26: 833–876
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick M F, Zuraw O C, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM Study. Clin Pract 2006; 60: 762–769
   Google Scholar
• Morales A, Lunenfeld B. International Society for the Study of the Aging Male. Investigation, treatment and monitoring of late-onset hypogonadism in male. Official recommendations of ISSAM. International Society of the Aging Male. The Aging Male 2002; 5: 74–86
   PubMedGoogle Scholar
• Nieschlag E, Swerdloff R, Behre H M, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM and EAU recommendations. The Aging Male 2005; 8: 56–58
   PubMedGoogle Scholar
• Lunenfeld B, Saad F, Hoesl C E, et al. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale. The Aging Male 2005; 8: 59–74
   PubMedGoogle Scholar
• Morley J E, Kaiser F E, Sih R, et al. Testosterone and frailty. Clin Geriatr Med 1997; 13: 685–694
   PubMed Web of Science ®Google Scholar
• Boonen S, Vanderschueren D, Geusens P, et al. Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men. Int J Androl 1997; 20: 134–143
   PubMedGoogle Scholar
• Kenny A M, Prestwood K M, Marcello K M, et al. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol 2000; 55A: M492–497
   Google Scholar
• Genant H K, Cann C E, Pozzi-Mucelli S, et al. Vertebral mineral determination by quantitative CT: clinical feasibility and normative data. J Comput Assist Tomogr 1981; 7: 554
   Web of Science ®Google Scholar
• Meier D E, Orwoll E S, Jones J M. Marked disparity between trabecular and cortical bone loss with age in healthy men. Ann Intern Med 1984; 101: 605–612
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F, et al. Body composition, sex steroids, IGF-1, and bone mineral status in aging men. J Gerontol 2000; 55A: M516–521
   Google Scholar
• van den Beld A W, de Jong F H, Grobbee D E, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276–3282
   PubMed Web of Science ®Google Scholar
• Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, et al. Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 1995; 43: 727–733
   PubMed Web of Science ®Google Scholar
• Greendale G A, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo Study. J Bone Miner Res 1997; 12: 1833–1843
   PubMed Web of Science ®Google Scholar
• Goldray D, Weisan Y, Jaccard N, et al. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Tryp6-GnRH). J Clin Endocrinol Metab 1993; 76: 288–290
   PubMed Web of Science ®Google Scholar
• Smith M R. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006; 12: 6315s–6319
   PubMed Web of Science ®Google Scholar
• Stanley H L, Schmitt B P, Poses R M, et al. Does hypogonadism contribute to the occurrence of minimal trauma hip fracture in elderly men?. J Am Gerontol Soc 1991; 39: 766–771
   Google Scholar
• Jackson J A, Riggs M W, Spiekerman A M. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 1992; 304: 4–8
   PubMed Web of Science ®Google Scholar
• Abbasi A A, Rudman D, Wilson C R, et al. Observations on nursing home residents with a history of hip fracture. Am J Med Sci 1995; 310: 229–234
   PubMed Web of Science ®Google Scholar
• Amin S, Zhang Y, Sawin C T, et al. Association of hypogonadism and estradiol level with bone mineral density in elderly men from the Framingham study. Ann Intern Med 2000; 133: 951–963
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton L J, Atkinson E J, et al. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555–3561
   PubMed Web of Science ®Google Scholar
• Kaufman J M. Role of sex steroids in the regulation of bone metabolism in the adult skeleton. Ann Endocrinol (Paris) 2006; 67: 119–122
   PubMed Web of Science ®Google Scholar
• Shreyasee A, Zhang Y, Felson D T, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham study. Am J Med 2006; 119: 426–433
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mueller J E, von Mühlen D G, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 219–223
   PubMed Web of Science ®Google Scholar
• Baumgartner R N, Waters D L, Gallagher D, et al. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Development 1999; 107: 123–136
   PubMed Web of Science ®Google Scholar
• Couillard C, Gagnon J, Bergeron J, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 2000; 85: 1026–1031
   PubMed Web of Science ®Google Scholar
• Tenover J S. Effects of testosterone supplementation in the aging male. J Clin Endocrinolo Metab 1992; 75: 1092–1098
   PubMed Web of Science ®Google Scholar
• Gooren L JG. Visceral obesity, androgens and the risk of cardiovascular disease and diabetes mellitus. The Aging Male 2001; 4: 30–38
   Google Scholar
• Stellato R K, Horton E S, Feldman H A, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men. Diabetes Care 2000; 23: 490–494
   PubMed Web of Science ®Google Scholar
• Lee C D, Blair S N, Jackson A S. Cardiorespiratory fitness, body composition, and all-cause cardiovascular disease mortality in men. Am J Clin Nutr 1999; 69: 373–380
   PubMed Web of Science ®Google Scholar
• Perry H M, Miller D K, Patrick P, et al. Testosterone and leptin in older African-American men: relationship to age, strength, function, and season. Metabolism 2000; 49: 1085–1091
   PubMed Web of Science ®Google Scholar
• Breuer B, Trungold S, Martucci C, et al. Relationship of sex hormone levels to dependence of daily living in the frail elderly. Maturitas 2001; 39: 147–159
   PubMed Web of Science ®Google Scholar
• Rolf C, von Eckardstein S, Koken U, et al. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body-mass index, body fat and leptin seen in healthy aging men. Results of a cross-sectional study. Eur J Endocrinol 2002; 146: 505–511
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer T W, Singh A B, . Testosterone effects on the skeletal muscle. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre, et al. Cambridge University Press, Cambridge 2004; 255–282
   Google Scholar
• Laumann E O, Paik A, Rosen R C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544
   PubMed Web of Science ®Google Scholar
• Meston C M. Aging and sexuality. West J Med 1997; 167: 285–290
   PubMedGoogle Scholar
• Schiavi R C, Schreiner-Engel P, White D, et al. The relationship between pituitary–gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991; 53: 363–374
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335–4343
   PubMed Web of Science ®Google Scholar
• Johannes C B, Araujo A B, Feldman H A, et al. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460–463
   PubMed Web of Science ®Google Scholar
• Carani C, Granata A RM, Bancroft J, et al. The effects of testosterone replacement on noctural penile tumescence and rigidity and erectile response to visual erotic stimuli in hypogonadal men. Psychoneuroendocrinology 1995; 20: 743–753
   PubMed Web of Science ®Google Scholar
• Behre H M. Testosterone and erection. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre. Cambridge University Press, Cambridge 2004; 333–346
   Google Scholar
• Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006; 60: 1087–1092
   PubMed Web of Science ®Google Scholar
• Spivak J L. The blood in systemic disorders. Lancet 2000; 355: 1707–1712
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Nieschlag E. Androgens and erythropoiesis. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre. Cambridge University Press, Cambridge 2004; 283–296
   Google Scholar
• Barrett-Connor E, Goodman-Gruen D, Patay B. Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab 1999; 84: 3681–3685
   PubMed Web of Science ®Google Scholar
• Yesavage J A, Davidson J, Widrow L, et al. Plasma testosterone levels, depression, sexuality, and age. Biol Psychiatr 1985; 20: 222–225
   PubMed Web of Science ®Google Scholar
• Burris A S, Banks S M, Carter C S, et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement therapy in untreated hypogonadal men. J Androl 1992; 13: 297–304
   PubMedGoogle Scholar
• Barrett-Connor E, von Mühlen D G, Kriz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573–577
   PubMed Web of Science ®Google Scholar
• Flood J F, Farr S A, Kaiser F E, et al. Age-related decrease of plasma testosterone in SAMP8 mice: replacement improves age-related impairment of learning and memory. Physiol Behav 1995; 57: 669–673
   PubMed Web of Science ®Google Scholar
• Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatr 1998; 155: 1310–1318
   PubMed Web of Science ®Google Scholar
• Goncharov N, Katsya G, Dobracheva A, et al. Serum testosterone measurement in men: evaluation of modern immunoassay technologies. The Aging Male 2005; 8: 194–202
   PubMedGoogle Scholar
• Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography–mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 1381–1395
   PubMed Web of Science ®Google Scholar
• Finkelstein J S, Kilbanski A, Neer R M, et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776
   PubMed Web of Science ®Google Scholar
• Tremblay R R, Morales A J. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. The Aging Male 1998; 1: 213
   Google Scholar
• Calof O M, Singh A B, Lee M L, et al. Adverse events assoicated with testoterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol 2005; 60A: 1451–1457
   Google Scholar
• Nieschlag E. Testosterone treatment comes of age – new options for hypogonadal men. Clin Endocrinol 2006; 65: 275–281
   PubMed Web of Science ®Google Scholar
• Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Bailliere's clinical endocrinology and metabolism: the therapeutic role of androgen. 1998; 521–534
   Google Scholar
• Zmuda J M, Cauley J A, Kriska A. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men. A 13 year follow-up of former risk factor intervention trial participants. Am J Epidemiol 1997; 146: 609–615
   PubMed Web of Science ®Google Scholar
• Phillips G B. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701–705
   PubMed Web of Science ®Google Scholar
• Uyanik B S, Ari Z, Gumus B, et al. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Japan Heart J 1997; 38: 73–77
   PubMedGoogle Scholar
• Crook D. Androgens and the risk of cardiovascular disease. The Aging Male 2000; 3: 190
   PubMedGoogle Scholar
• Tenover J L. Testosterone and the aging male. J Androl 1997; 18: 103–106
   PubMed Web of Science ®Google Scholar
• Behre H M, Bohmeyer J, Nieschlag E. Prostate volume in treated and untreated hypogonadal men in comparison to age matched controls. Clin Endocrinol 1994; 40: 341–346
   PubMed Web of Science ®Google Scholar
• Cooper C S, Perry P J, Sparks A E, et al. Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998; 159: 441–443
   PubMed Web of Science ®Google Scholar
• Holmäng S, Marin P, Lindtstedt G, et al. Effect of long term oral testosterone undecanoate treatment on prostate volume and serum prostate specific antigen in eugonadal middle-aged men. Prostate 1993; 23: 99–106
   PubMed Web of Science ®Google Scholar
• Nomura A, Heilrunn L K, Stemmermann G N, et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1998; 48: 3515–3520
   Google Scholar
• Curran M J, Bihrle W. Dramatic rise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53: 423–424
   PubMed Web of Science ®Google Scholar
• Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men – A clinical research center study. J Clin Endocrin Metab 1996; 81: 3587–3593
   Web of Science ®Google Scholar
• Ehrenreich H, Halaris A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res 1999; 33: 379–387
   PubMed Web of Science ®Google Scholar
• Ozata M, Odabasi Z, Caglayan S, et al. Event related male potentials in male hypogonadism. J Endocrinol Invest 1999; 22: 508–513
   PubMed Web of Science ®Google Scholar
• Morales A, Connolly J, Burr R, et al. The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate. Can Med Assoc J 1970; 103: 372–373
   PubMed Web of Science ®Google Scholar
• Sandbloom R A, Matsumoto A M, Schoene R B, et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983; 308: 508–510
   PubMed Web of Science ®Google Scholar
• Santamaria J D, Prior J C, Fleetham J A. Reversible reproductive dysfunction in men with sleep apnea. Clin Endocrinol (Oxf) 1988; 28: 461–470
   PubMed Web of Science ®Google Scholar
• Werner A A. The male climacteric: additional observations of thirty-seven patients. J Urol 1943; 49: 872–882
   Google Scholar
• Heller C G, Myers G B. The male climacteric, its symptomatology, diagnosis and treatment. JAMA 1944; 126: 472–477
   Google Scholar
• Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 1992; 2: 991–997
   Google Scholar
• Marin P. Testosterone and regional fat distribution. Obes Res 1995; 3: 609–612
   PubMedGoogle Scholar
• Snyder P J, Peachy H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Berlin J A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670–2677
   PubMed Web of Science ®Google Scholar
• Arver S, Meikle A W, Dobbs A S, et al. Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J Endocrinol 1996; 148: 254–259
   Google Scholar
• Bebb R A, Wade J, Frohlich J, et al. A randomized, double blind, placebo controlled trial of testosterone undecanoate administration in aging hypogonadal men: effects on bone density and body composition. The Aging Male 2000; 3: 22
   Google Scholar
• Wang C, Swerdloff R S, Iranmanesch A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85: 2839–2853
   PubMed Web of Science ®Google Scholar
• Wittert G A, Chapman I M, Haren M T, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol 2003; 58A: 618–625
   Google Scholar
• Webb C M, McNeill J G, Hayward C S, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690–1696
   PubMed Web of Science ®Google Scholar
• Morley J E, Perry H M, Kaiser F E, et al. Effect of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–152
   PubMed Web of Science ®Google Scholar
• Hajjar R R, Kaiser F E, Morley J E. Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J Clin Endocrinol Metab 1997; 82: 3793–3796
   PubMed Web of Science ®Google Scholar
• Kalintchenko S Y, Kozlov G I, Gontcharov N P, et al. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. The Aging Male 2003; 6: 94–99
   PubMedGoogle Scholar
• McKeever W F, Deyo A. Testosterone, dihydrotestosterone and spatial task performance of males. Bull Psychonomic Soc 1990; 28: 305–308
   Google Scholar
• Christiansen K. Behavioural correlates of testosterone. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre. Cambridge University Press, Cambridge 2004; 125–172
   Google Scholar
• Zitzmann M, Weckesser M, Schober O, et al. Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diab 2001; 109: 302–304
   PubMed Web of Science ®Google Scholar
• Wolf O T, Preut R, Hellhammer D H, et al. Testosterone and cognition in elderly men: a single testosterone injection blocks the practice effect in verbal fluency, but has no effect on spatial or verbal memory. Biol Psychiatry 2000; 47: 650–654
   PubMed Web of Science ®Google Scholar
• Janowsky J S, Oviatt S K, Orwoll E S. Testosterone influences spatial cognition in older men. Behav Neurosci 1994; 108: 325–332
   PubMed Web of Science ®Google Scholar
• Azad N, Pitale S, Barnes W E, et al. Testosterone treatment enhances regional brain perfusion in hypogonadal men. J Clin Endocrinol Metab 2003; 88: 3064–3068
   PubMed Web of Science ®Google Scholar
• Behre H M, Wang C, Handelsman D, . Pharmacology of testosterone preparations. Testosterone: action, deficiency, substitution, E Nieschlag, H M Behre, et al. Cambridge University Press, Cambridge 2004; 405–444
   Google Scholar
• Nieschlag E. If testosterone, which testosterone? Which androgen regimen should be used for supplementation in older men? Formulation, dosing and monitoring issues. J Clin Endocrinol Metab 1998; 83: 3443–3445
   Google Scholar
• Jockenhövel F, Vogel E, Kreutzer M, et al. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol 1996; 45: 61–71
   PubMed Web of Science ®Google Scholar
• Kelleher S, Howe C, Conway A J, et al. Testosterone release rate and duration of action of testosterone pellets implants. Clin Endocrinol 2004; 60: 4220–4228
   Web of Science ®Google Scholar
• Handelsman D J, Conway A J, Boylan L M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990; 71: 216–222
   PubMed Web of Science ®Google Scholar
• Kelleher S, Turner L, Howe C, et al. Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol 1999; 51: 469–471
   PubMed Web of Science ®Google Scholar
• Handelsman D J, Mackey M A, Howe C, et al. An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol 1997; 47: 311–316
   PubMed Web of Science ®Google Scholar
• Kelleher S, Conway A J, Handelsman D J. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol 2001; 55: 531–536
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Mauss J, Coert A, et al. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol 1975; 79: 366–374
   PubMedGoogle Scholar
• Bagchus W M, et al. Bioequivalence of Andriol and Andriol Testocaps. The Aging Male 2001; 4: 259
   Google Scholar
• Bagchus W M, Hust R, Maris F, et al. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 2003; 23: 319–325
   PubMed Web of Science ®Google Scholar
• Charman W N, Porter C JH. Lipophilic prodrugs designed for intestinal lymphatic tranport. Adv Drug Deliv Rev 1996; 19: 149–169
   Web of Science ®Google Scholar
• Noguchi T, Charman W N, Stella V J. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters. Int J Pharm 1985; 173–184
   Google Scholar
• Gooren L J, Bunck M C. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861–1891
   PubMed Web of Science ®Google Scholar
• Gooren L J. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212–215
   PubMed Web of Science ®Google Scholar
• Schürmeyer T H, Wickings E J, Freischem C W, et al. Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 1983; 102: 456–462
   PubMedGoogle Scholar
• Park N C, Yan B Q, Chung J M, et al. Oral testosterone undecanoate (Andriol®) supplement therapy improves the quality of life for men with testosterone deficiency. The Aging Male 2003; 6: 86–93
   PubMedGoogle Scholar
• Gooren L J. Long-term safety of the oral androgen testosterone undecanoate. Int J Androl 1986; 9: 21–26
   PubMedGoogle Scholar
• Wang C, Swerdloff R, Kipnes M, et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3821–3829
   PubMed Web of Science ®Google Scholar
• Korbonits M, Slawik M, Cullen D, et al. A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 2004; 89: 2039–2043
   PubMed Web of Science ®Google Scholar
• Sokol R Z, Palacios A, Campfield L A. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37: 425–430
   PubMed Web of Science ®Google Scholar
• Schürmeyer T, Nieschlag E. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 1984; 7: 181–187
   PubMed Web of Science ®Google Scholar
• Jockenhövel F, Vogel E, Reinhardt W, et al. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997; 2: 293–298
   PubMedGoogle Scholar
• Schulte-Beerbühl M, Nieschlag E. Comparison of testosterone, DHT, LH and FSH in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril 1980; 33: 201–203
   PubMed Web of Science ®Google Scholar
• Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 1221–1224
   PubMed Web of Science ®Google Scholar
• Yates W R, Perry P J, MacIndoe J, et al. Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol Psychiat 1999; 45: 254–260
   PubMed Web of Science ®Google Scholar
• Behre H M, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999; 140: 414–419
   PubMed Web of Science ®Google Scholar
• Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004; 89: 5429–5434
   PubMed Web of Science ®Google Scholar
• Harle L, Basaria S, Dobbs A S. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadsim. Expert Opin Pharmacother 2005; 6: 1751–1759
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Büchter D, von Eckardstein S, et al. Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogonadal men. Clin Endocrinol 1999; 51: 757–763
   PubMed Web of Science ®Google Scholar
• von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks, A phase II study. J Androl 2002; 23: 419–425
   PubMedGoogle Scholar
• De Sanctis V, Vullo C, Urso L, et al. Clinical experience using Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Peditr Endocrinol Metab 1999; 11(Suppl. 3)891–900
   Google Scholar
• Dobbs A S, Meikle A W, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469–3478
   PubMed Web of Science ®Google Scholar
• Arver S, Dobbs A S, Meile A W, et al. Long-term efficacy and safety of a permeation enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: 727–737
   PubMed Web of Science ®Google Scholar
• Meikle A W, Matthias D, Hoffman A R. Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men. BJU 2004; 93: 789–795
   PubMed Web of Science ®Google Scholar
• Wang C, Berman N, Longstreth J A, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000; 85: 964–969
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobbs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff R S, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839
   PubMed Web of Science ®Google Scholar
• Rolf C, Knie U, Lemmnitz G, et al. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol 2002; 56: 637–641
   PubMed Web of Science ®Google Scholar
• Kühnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol 2005; 153: 317–326
   PubMed Web of Science ®Google Scholar
• Behre H M, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386
   PubMed Web of Science ®Google Scholar